Ozmosi | Aldesleukin Drug Profile

Product Description

Aldesleukin is used to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the kidney) that has spread to other parts of your body. Aldesleukin is also used to treat melanoma (a type of skin cancer) that has spread to other parts of your body. Aldesleukin is in a class of drugs known as cytokines. It is a man-made version of a naturally occurring protein that stimulates the body to produce other chemicals which increase the body's ability to fight cancer. (Sourced from: https://medlineplus.gov/druginfo/meds/a692009.html)

Mechanisms of Action: IL2 Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous, Subcutaneous

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Company: Chiron
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aldesleukin

Countries in Clinic: China, France, Germany, Hong Kong, Israel, New Zealand, United Kingdom, United States

Active Clinical Trial Count: 19

Recent & Upcoming Milestones

Highest Development Phases

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT07192900	(RIOT 4A)	P1	Recruiting	Pleural Effusion, Malignant\|Mesothelioma	2032-12-01	12%	2026-01-16
NCT05483491	Pro2022002198	P1	Recruiting	Gastrointestinal Cancer\|Uterine Cancer\|Cervical Cancer\|Lung Cancer\|Breast Cancer	2026-09-01	12%	2024-07-13
NCT05153070	DF-IL2-REP	P2	Recruiting	Type 1 Diabetes	2026-04-21		2024-11-22
NCT05468073	IL-2-AD	P2	Recruiting	Alzheimer Disease	2025-09-01		2024-06-28	Primary Endpoints
NCT04426669	2019LS002	P2	Completed	Colorectal Cancer\|Esophageal Cancer\|Pancreatic Cancer\|Gallbladder Cancer\|Gastrointestinal Cancer	2025-05-28		2026-02-24	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
2012-001786-32	IL2HD	P2	Completed	Renal Cell Carcinoma\|Melanoma	2024-12-31		2025-05-06	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
NCT03782636	ITAD	P2	Active, not recruiting	Type 1 Diabetes\|Diabetes Complications	2023-02-16		2025-10-04	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT07589842	ALaDIN	P2	Not yet recruiting	Autism Spectrum Disorder	2028-11-30	12%	2026-05-16	Primary Endpoints\|Treatments
NCT07288073	NCT07288073	P2	Recruiting	Carcinoma, Merkel Cell\|Cutaneous Squamous Cell Carcinoma\|Skin Cancer\|Squamous Cell Carcinoma	2028-09-29	12%	2026-02-14	Primary Endpoints\|Start Date
NCT05296564	0752-20-HMO	P2	Recruiting	Neuroblastoma\|Non-Small-Cell Lung Cancer\|Transitional Cell Carcinoma\|Bladder Cancer\|Triple Negative Breast Cancer\|Soft Tissue Cancer\|Ovarian Cancer\|Melanoma\|Synovial Sarcoma	2027-12-30		2023-09-26	Primary Endpoints\|Treatments
NCT07255664	ProbeTILity	P2	Recruiting	Colorectal Cancer\|Prostate Cancer	2027-04-01	55%	2025-12-11	Primary Endpoints\|Start Date\|Treatments\|Trial Status
NCT05686226	Pro2022002259	P2	Recruiting	Head and Neck Cancer\|Colorectal Cancer\|Anus Cancer\|Adenocarcinoma\|Squamous Cell Carcinoma\|Anal Cancer\|Oropharyngeal Cancer\|Vulvar Cancer\|Penile Cancer\|Cervical Cancer\|Carcinoma, Adenosquamous\|Vaginal Cancer\|Uterine Cancer	2027-01-01	59%	2025-04-01	Primary Completion Date\|Primary Endpoints
NCT05639972	Pro2022000437	P2	Recruiting	Head and Neck Cancer\|Anus Cancer\|Vulvar Cancer\|Uterine Cancer\|Oropharyngeal Cancer\|Anal Cancer\|Carcinoma, Adenosquamous\|Adenocarcinoma\|Cervical Cancer\|Squamous Cell Carcinoma\|Vaginal Cancer\|Penile Cancer	2026-10-01	66%	2025-04-01	Primary Endpoints\|Start Date\|Treatments\|Trial Status
2020-003629-45	Study of LN 145 in patients with Metastatic Non-Small-Cell Lung Cancer	P2	Active, not recruiting	Non-Small-Cell Lung Cancer	2026-05-05	51%	2022-03-13	Treatments
ACTRN12618001843246p	2006-7041-83/hah	P1	Not yet recruiting	Hepatitis B	None
CTR20231525	CTR20231525	P1	Active, not recruiting	Oncology Solid Tumor Unspecified	None		2025-04-29
2025-521227-70-00	ProbeTILity	P2	Not yet recruiting	Colorectal Cancer\|Prostate Cancer	2029-03-01	55%
2012-001410-41	ABSIDE	P2	Completed	Melanoma	2024-06-20		2025-05-06	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
2020-005068-70	DFIL2-REP	P2	Active, not recruiting	Unknown	2022-12-07		2022-03-13	Treatments

Recent News Events

Date	Type	Title
04/17/2026	News Article	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
03/20/2026	News Article	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
02/05/2026	News Article	Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
01/16/2026	News Article	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Aldesleukin

Alternative Names: aldesleukin, proleukin, recombinant human interleukin-2, ril-2, ilt-101, ilt101 Clinical Status: Inactive Latest Update: 2026-06-25 Latest Update Note: Clinical Trial Update